{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:05:31Z","timestamp":1785326731180,"version":"3.55.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Complement factor H (FH), encoded by CFH, is a principal soluble regulator of the alternative complement pathway, but its roles in cancer extend beyond extracellular complement control. Intracellular FH has been linked to p53\/NF-\u03baB signaling, cell-cycle regulation, and cytoskeletal organization. Recent studies distinguish a nuclear FH\u2013E2F3 interaction associated with p53 and cell-cycle control from a cytosolic FH\u2013CapZ-associated mechanism involved in actin organization. Although FH has been detected in lysosome-positive compartments, current evidence does not establish lysosomes as the functional site of these intracellular effects. At the tumor\u2013host interface, extracellular FH protects tumor-cell and extracellular-vesicle surfaces from complement-mediated injury and phagocytic clearance. Locally produced FH and FHL-1 have also been associated with distinct myeloid-cell and regulatory T-cell programs, including direct FH\u2013ICOS engagement. Structurally altered tumor-associated FH can become a target of endogenous anti-FH antibodies and of the therapeutic antibody GT103, linking local complement regulation with humoral recognition and therapeutic intervention. Across tissues and circulation, FH exists in intracellular, soluble, surface-associated, and extracellular-vesicle-associated pools shaped by hepatic production, local synthesis, surface recruitment, distribution, and clearance. These pools are not interchangeable: their functions and clinical associations depend on both source and compartment. We therefore propose a source- and compartment-resolved framework that separates systemic FH availability from local intracellular and extracellular functions, while treating cross-compartment relationships as testable rather than established causal sequences. Tissue and circulating FH measurements are being explored as context-dependent biomarkers, and GT103 has progressed through phase Ib and completed phase II evaluation in refractory non-small cell lung cancer. Further progress will require tissue-specific experimental models, paired tissue and circulating measurements, clearer mapping of intracellular interaction sites, and biomarker analyses that account separately for hepatic production, inflammatory state, renal handling or protein loss, and altered distribution or clearance.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1877625","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:18:00Z","timestamp":1785323880000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Complement factor H in cancer biology: intracellular functions, tumor\u2013host interactions, and systemic context"],"prefix":"10.3389","volume":"17","author":[{"given":"Xitan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Oncology, Zibo Central Hospital","place":["Zibo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiying","family":"Mu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Zibo Central Hospital","place":["Zibo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Zibo Central Hospital","place":["Zibo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrneph.2017.156","article-title":"The renaissance of complement therapeutics","volume":"14","author":"Ricklin","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.10.018","article-title":"Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation","volume":"39","author":"Liszewski","year":"2013","journal-title":"Immunity"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0168-x","article-title":"New insights into the immune functions of complement","volume":"19","author":"Reis","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013290","article-title":"Complement system in cancer: friend or foe of immunotherapy","volume":"14","author":"Shah","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1655","article-title":"Modulation of the antitumor immune response by complement","volume":"9","author":"Markiewski","year":"2008","journal-title":"Nat Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nri.2017.97","article-title":"Complement in cancer: untangling an intricate relationship","volume":"18","author":"Reis","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2025.101950","article-title":"Complement and the hallmarks of cancer","volume":"78","author":"Artero","year":"2025","journal-title":"Semin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201546131","article-title":"A novel \"complement-metabolism-inflammasome axis\" as a key regulator of immune cell effector function","volume":"46","author":"Arbore","year":"2016","journal-title":"Eur J Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41698-025-00848-2","article-title":"Complement activation in tumor microenvironment after neoadjuvant therapy and its impact on pancreatic cancer outcomes","volume":"9","author":"Zhang","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2418-4","article-title":"Complement factor H in host defense and immune evasion","volume":"74","author":"Parente","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1021\/bi4003452","article-title":"Functional anatomy of complement factor H","volume":"52","author":"Makou","year":"2013","journal-title":"Biochemistry"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2013.06.001","article-title":"Complement factor H related proteins (CFHRs)","volume":"56","author":"Skerka","year":"2013","journal-title":"Mol Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1135490","article-title":"The human factor H protein family - an update","volume":"15","author":"S\u00e1ndor","year":"2024","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/nep.14304","article-title":"Characterization of patients with aHUS and associated triggers or clinical conditions: A Global aHUS Registry analysis","volume":"29","author":"Licht","year":"2024","journal-title":"Nephrol (Carlton)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.670727","article-title":"CFH and CFHR copy number variations in C3 glomerulopathy and immune complex-mediated membranoproliferative glomerulonephritis","volume":"12","author":"Piras","year":"2021","journal-title":"Front Genet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/science.1109557","article-title":"Complement factor H polymorphism in age-related macular degeneration","volume":"308","author":"Klein","year":"2005","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2008.04.008","article-title":"Factor H family proteins and human diseases","volume":"29","author":"J\u00f3zsi","year":"2008","journal-title":"Trends Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-20-0787","article-title":"Intracellular factor H drives tumor progression independently of the complement cascade","volume":"9","author":"Daugan","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s42003-026-09807-4","article-title":"Intracellular complement Factor H promotes tumor progression through modulation of cell cycle and actin cytoskeleton","volume":"9","author":"Rezola Artero","year":"2026","journal-title":"Commun Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252577","article-title":"Complement factor H protects tumor cell-derived exosomes from complement-dependent lysis and phagocytosis","volume":"16","author":"Bushey","year":"2021","journal-title":"PloS One"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.Epi-10-0467","article-title":"Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer","volume":"19","author":"Pio","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.312","article-title":"Identification of stromally expressed molecules in the prostate by tag-profiling of cancer-associated fibroblasts, normal fibroblasts and fetal prostate","volume":"31","author":"Orr","year":"2012","journal-title":"Oncogene"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-21-1392","article-title":"Tumor cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma","volume":"27","author":"Zhai","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-23-1092","article-title":"Complement factor H is an ICOS ligand modulating Tregs in the glioma microenvironment","volume":"13","author":"Smolag","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3233\/cbm-210355","article-title":"Prognostic significance of a complement factor H autoantibody in early stage NSCLC","volume":"34","author":"Gottlin","year":"2022","journal-title":"Cancer biomark"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-10-0321","article-title":"Complement factor H autoantibodies are associated with early stage NSCLC","volume":"16","author":"Amornsiripanitch","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-025-03382-4","article-title":"Circulating extracellular vesicles protein expression for early prediction of platinum-resistance in high-grade serous ovarian cancer","volume":"44","author":"Wagner","year":"2025","journal-title":"Oncogene"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.2289","article-title":"Association of KDR (rs2071559, rs1870377), CFH (rs1061170, rs1410996) genes variants and serum levels with pituitary adenoma","volume":"12","author":"Bruzaite","year":"2024","journal-title":"Mol Genet Genomic Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2021-141186","article-title":"Low level of complement factor H increases the risk of cancer-related death in patients with small-cell lung cancer","volume":"98","author":"Xiang","year":"2022","journal-title":"Postgrad Med J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41467-024-55092-2","article-title":"Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial","volume":"16","author":"Clarke","year":"2025","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70141","article-title":"A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer","volume":"131","author":"Mamdani","year":"2025","journal-title":"Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/jid.2013.346","article-title":"Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma","volume":"134","author":"Riihil\u00e4","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11040471","article-title":"Upregulation of complement factor H by SOCS-1\/3-STAT4 in lung cancer","volume":"11","author":"Yoon","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2011.26.11.1428","article-title":"Genes associated with recurrence of hepatocellular carcinoma: integrated analysis by gene expression and methylation profiling","volume":"26","author":"Yang","year":"2011","journal-title":"J Korean Med Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.15580","article-title":"Bioinformatic identification of differentially expressed genes regulated by DNA-methylation in glioblastoma","volume":"55","author":"Guan","year":"2022","journal-title":"Eur J Neurosci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7394","article-title":"Impact of genomic and epigenomic alterations of multigene on a multicancer pedigree","volume":"13","author":"Gao","year":"2024","journal-title":"Cancer Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1515\/biol-2022-0029","article-title":"circ-CFH promotes the development of HCC by regulating cell proliferation, apoptosis, migration, invasion, and glycolysis through the miR-377-3p\/RNF38 axis","volume":"17","author":"Chen","year":"2022","journal-title":"Open Life Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.12659\/msm.910180","article-title":"Circular RNA complement factor H (CFH) promotes glioma progression by sponging miR-149 and regulating AKT1","volume":"24","author":"Bian","year":"2018","journal-title":"Med Sci Monit"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.033","article-title":"Local complement factor H protects kidney endothelial cell structure and function","volume":"100","author":"Mahajan","year":"2021","journal-title":"Kidney Int"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168727","article-title":"CFH loss in human RPE cells leads to inflammation and complement system dysregulation via the NF-\u03baB pathway","volume":"22","author":"Armento","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/j.immuni.2023.06.026","article-title":"Cell-autonomous regulation of complement C3 by factor H limits macrophage efferocytosis and exacerbates atherosclerosis","volume":"56","author":"Kiss","year":"2023","journal-title":"Immunity"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2025.118335","article-title":"Target complement factor H\/serum amyloid A signaling in trichloroethylene-induced immune kidney injury","volume":"298","author":"Xie","year":"2025","journal-title":"Ecotoxicol Environ Saf"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114544","article-title":"Glomerular mesangial cells derived complement factor H regulates complement activation, influences cell proliferation, and maintains actin cytoskeleton","volume":"154","author":"Li","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2018.07.023","article-title":"Absence of complement factor H alters bone architecture and dynamics","volume":"223","author":"Alexander","year":"2018","journal-title":"Immunobiology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-22-0723","article-title":"Antitumor immune mechanisms of the anti-complement factor H antibody GT103","volume":"22","author":"Bushey","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.107078","article-title":"Oral squamous cell carcinomas drive monocytes into immunosuppressive CD25(+)CD163(+)CD206(+) macrophages","volume":"159","author":"Pelaez-Prestel","year":"2024","journal-title":"Oral Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01607","article-title":"Complement factor H modulates splenic B cell development and limits autoantibody production","volume":"10","author":"Kiss","year":"2019","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s00262-025-03975-8","article-title":"A tumor-binding antibody with cross-reactivity to viral antigens","volume":"74","author":"Campa","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2024.2328433","article-title":"Humoral complementomics - exploration of noninvasive complement biomarkers as predictors of renal cancer progression","volume":"13","author":"Revel","year":"2024","journal-title":"Oncoimmunology"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2300728","article-title":"Promotion of an antitumor immune program by a tumor-specific, complement-activating antibody","volume":"212","author":"Saxena","year":"2024","journal-title":"J\u00a0Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0804179","article-title":"The regulation of liver cell survival by complement","volume":"182","author":"Markiewski","year":"2009","journal-title":"J Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30508","article-title":"The role of complement in liver injury, regeneration, and transplantation","volume":"70","author":"Thorgersen","year":"2019","journal-title":"Hepatology"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.18632\/aging.204178","article-title":"The miR-590-3p\/CFHR3\/STAT3 signaling pathway promotes cell proliferation and metastasis in hepatocellular carcinoma","volume":"14","author":"Wan","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2022.2073943","article-title":"A novel hypoxia-driven gene signature that can predict the prognosis of hepatocellular carcinoma","volume":"13","author":"Zeng","year":"2022","journal-title":"Bioengineered"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.29551","article-title":"CFHR3 is a potential novel biomarker for hepatocellular carcinoma","volume":"121","author":"Liu","year":"2020","journal-title":"J Cell Biochem"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2020.4998","article-title":"Immune system-associated genes increase\u00a0Malignant progression and can be used to predict clinical outcome in patients with hepatocellular carcinoma","volume":"56","author":"Huang","year":"2020","journal-title":"Int J Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2019.7455","article-title":"Downregulated expression of CFHL1 is associated with unfavorable prognosis in postoperative patients with hepatocellular carcinoma","volume":"17","author":"Feng","year":"2019","journal-title":"Exp Ther Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.812663","article-title":"Identification of CFHR4 associated with poor prognosis of hepatocellular carcinoma","volume":"12","author":"Ding","year":"2022","journal-title":"Front Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1752827","article-title":"Low complement factor H-related 3 (CFHR3) expression indicates poor prognosis and immune regulation in cholangiocarcinoma","volume":"2022","author":"Wang","year":"2022","journal-title":"J Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2018.07.003","article-title":"Electrochemical ELISA-based platform for bladder cancer protein biomarker detection in urine","volume":"117","author":"Arya","year":"2018","journal-title":"Biosens Bioelectron"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.3c01786","article-title":"Ultrasensitive electrochemiluminescence immunosensor for bladder marker human complement factor H-related protein detection","volume":"95","author":"Zhang","year":"2023","journal-title":"Anal Chem"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-012-0935-9","article-title":"Urinary BTA: indicator of bladder cancer or of hematuria","volume":"30","author":"Miyake","year":"2012","journal-title":"World J Urol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1021\/pr400169n","article-title":"Altered expression of sialylated glycoproteins in ovarian cancer sera using lectin-based ELISA assay and quantitative glycoproteomics analysis","volume":"12","author":"Wu","year":"2013","journal-title":"J Proteome Res"},{"key":"B65","article-title":"Identification of biomarkers for ovarian cancer diagnosis and prognosis by bioinformatics analysis and q-PCR validation","volume":"52","author":"Zheng","year":"2022","journal-title":"Ann Clin Lab Sci"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132162","article-title":"Serum complement factor H: a marker for progression and outcome prediction towards immunotherapy in cutaneous squamous cell carcinoma","volume":"17","author":"Geidel","year":"2025","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1877625\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:18:02Z","timestamp":1785323882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1877625\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2026.1877625"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1877625","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1877625"}}